Status:
COMPLETED
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
Lead Sponsor:
Eli Lilly and Company
Conditions:
Diabetic Peripheral Neuropathy
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately ...
Eligibility Criteria
Inclusion
- Have a history and current diagnosis of Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D) diagnosed for at least 6 months prior to screening.
- Have a stable glycemic control on stable diabetes treatment regimen for at least 90 days prior to day 1 with a hemoglobin A1c (HbA1c) ≤10 for T1D and HbA1c ≤11 for participants with T2D at time of screening.
- Have a history of daily peripheral neuropathic pain for at least 12 weeks based on participant report or medical history.
- Have a visual analog scale (VAS) pain value ≥40 and \<95 during screening.
- Have presence of diabetic peripheral neuropathy of symmetrical nature and in lower extremities for ≥6 months and diagnosed by a score of Part B ≥3 on Michigan Neuropathy Screening Instrument
- Are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation.
- Are willing to discontinue all medications taken for chronic pain conditions, except allowed concomitant pain medication permitted per protocol, for the duration of the study
- Have a body mass index ≤45 kilogram/square meter (kg/m²) (inclusive).
- Are men, or women able to abide by reproductive and contraceptive requirements.
Exclusion
- History of other potentially causative and/or confounding sources of pain that may impair self-assessment of pain due to DPNP.
- Have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques.
- Have had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision.
- Are, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide.
- Have in the judgement of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation.
- Have a positive HIV test result at screening.
- Have a surgery planned during the study for any reason.
- Have a substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5; American Psychiatric Association)
Key Trial Info
Start Date :
October 5 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 11 2025
Estimated Enrollment :
405 Patients enrolled
Trial Details
Trial ID
NCT06074562
Start Date
October 5 2023
End Date
June 11 2025
Last Update
July 3 2025
Active Locations (70)
Enter a location and click search to find clinical trials sorted by distance.
1
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
Chandler, Arizona, United States, 85225
2
Headlands Research - Scottsdale
Scottsdale, Arizona, United States, 85260
3
Orange Grove Family Practice
Tucson, Arizona, United States, 85741
4
Preferred Research Partners
Little Rock, Arkansas, United States, 72211